CHRS Relative Valuation
CHRS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CHRS is overvalued; if below, it's undervalued.
Historical Valuation
Coherus Oncology Inc (CHRS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -7.60. The fair price of Coherus Oncology Inc (CHRS) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 1.22 USD , Coherus Oncology Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：1.22
Fair
Undervalued
-1.76
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Coherus Oncology Inc. (CHRS) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -15.11. The thresholds are as follows: Strongly Undervalued below -140.56, Undervalued between -140.56 and -77.83, Fairly Valued between 47.61 and -77.83, Overvalued between 47.61 and 110.34, and Strongly Overvalued above 110.34. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.07
EV/EBIT
Coherus Oncology Inc. (CHRS) has a current EV/EBIT of -0.07. The 5-year average EV/EBIT is -3.06. The thresholds are as follows: Strongly Undervalued below -43.31, Undervalued between -43.31 and -23.19, Fairly Valued between 17.07 and -23.19, Overvalued between 17.07 and 37.20, and Strongly Overvalued above 37.20. The current Forward EV/EBIT of -0.07 falls within the Historic Trend Line -Fairly Valued range.
1.58
PS
Coherus Oncology Inc. (CHRS) has a current PS of 1.58. The 5-year average PS is 2.04. The thresholds are as follows: Strongly Undervalued below -0.38, Undervalued between -0.38 and 0.83, Fairly Valued between 3.24 and 0.83, Overvalued between 3.24 and 4.45, and Strongly Overvalued above 4.45. The current Forward PS of 1.58 falls within the Historic Trend Line -Fairly Valued range.
-1.58
P/OCF
Coherus Oncology Inc. (CHRS) has a current P/OCF of -1.58. The 5-year average P/OCF is 2.09. The thresholds are as follows: Strongly Undervalued below -48.59, Undervalued between -48.59 and -23.25, Fairly Valued between 27.43 and -23.25, Overvalued between 27.43 and 52.77, and Strongly Overvalued above 52.77. The current Forward P/OCF of -1.58 falls within the Historic Trend Line -Fairly Valued range.
-1.71
P/FCF
Coherus Oncology Inc. (CHRS) has a current P/FCF of -1.71. The 5-year average P/FCF is -11.08. The thresholds are as follows: Strongly Undervalued below -59.38, Undervalued between -59.38 and -35.23, Fairly Valued between 13.07 and -35.23, Overvalued between 13.07 and 37.22, and Strongly Overvalued above 37.22. The current Forward P/FCF of -1.71 falls within the Historic Trend Line -Fairly Valued range.
Coherus Oncology Inc (CHRS) has a current Price-to-Book (P/B) ratio of 1.62. Compared to its 3-year average P/B ratio of -1.70 , the current P/B ratio is approximately -195.15% higher. Relative to its 5-year average P/B ratio of 1.74, the current P/B ratio is about -6.90% higher. Coherus Oncology Inc (CHRS) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -51.76%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -32.05% , the current FCF yield is about -100.00% lower.
1.63
P/B
Median3y
-1.70
Median5y
1.74
-61.16
FCF Yield
Median3y
-51.76
Median5y
-32.05
Competitors Valuation Multiple
The average P/S ratio for CHRS's competitors is 0.96, providing a benchmark for relative valuation. Coherus Oncology Inc Corp (CHRS) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 91.19%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CHRS decreased by 10.87% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 6.05M to 11.57M.
The secondary factor is the P/E Change, contributed -50.98%to the performance.
Overall, the performance of CHRS in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Coherus Oncology Inc (CHRS) currently overvalued or undervalued?
What is Coherus Oncology Inc (CHRS) fair value?
How does CHRS's valuation metrics compare to the industry average?
What is the current P/B ratio for Coherus Oncology Inc (CHRS) as of Dec 05 2025?
What is the current FCF Yield for Coherus Oncology Inc (CHRS) as of Dec 05 2025?
What is the current Forward P/E ratio for Coherus Oncology Inc (CHRS) as of Dec 05 2025?